Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease

Kidney International

Volumn 77, Issue 11, 2012, Pages 989-999

  Veron, Delma ^a   Reidy, Kimberly J ^b   Bertuccio, Claudia ^a   Teichman, Jason ^b   Villegas, Guillermo ^b   Jimenez, Juan ^b   Shen, Wa ^b   Kopp, Jeffrey B ^c   Thomas, David B ^b   Tufro, Alda ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

diabetic glomerulopathy; nephrin; podocyte; proteinuria; VEGF

Indexed keywords

DOXYCYCLINE; GELATINASE B; NEPHRIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; MEMBRANE PROTEIN; MMP9 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; CELL EXPANSION; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; GLOMERULOPATHY; GLOMERULUS BASEMENT MEMBRANE; IN VIVO STUDY; MESANGIUM CELL; MOUSE; NONHUMAN; PARACRINE SIGNALING; PATHOGENESIS; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEINURIA; AGE; ANIMAL; DIABETIC NEPHROPATHY; GENETICS; GENOTYPE; KIDNEY DISEASE; METABOLISM; PATHOLOGY; PHENOTYPE; PHOSPHORYLATION; PROTEIN BINDING; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; UPREGULATION;

AGE FACTORS; ANIMALS; AUTOCRINE COMMUNICATION; DIABETIC NEPHROPATHIES; GENOTYPE; GLOMERULAR BASEMENT MEMBRANE; KIDNEY DISEASES; MATRIX METALLOPROTEINASE 9; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; PARACRINE COMMUNICATION; PHENOTYPE; PHOSPHORYLATION; PODOCYTES; PROTEIN BINDING; PROTEINURIA; SIGNAL TRANSDUCTION; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 77955870854     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.64     Document Type: Article

References (41)

1. Coultas L, Chawengsaksophak K, Rossant J. Endothelial cells and VEGF in vascular development. Nature 2005; 438: 937-945. (Pubitemid 43093959)
2. Carmeliet P, Ferreira V, Breier G et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380: 435-439. (Pubitemid 26102719)
3. Ferrara N, Carver-Moore K, Chen H et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380: 439-442. (Pubitemid 26102720)
4. Eremina V, Cui S, Gerber H et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111: 707-716. (Pubitemid 36278589)
5. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004; 65: 2003-2017. (Pubitemid 38669987)
6. Quaggin SE, Coffman TM. Toward a mouse model of diabetic nephropathy: is endothelial nitric oxide synthase the missing link? J Am Soc Nephrol 2007; 18: 364-367.
7. Cooper ME, Vranes D, Youssef S et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999; 48: 2229-2239. (Pubitemid 29521855)
8. De Vriese AS, Tilton RG, Elger M et al. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001; 12: 993-1000. (Pubitemid 32378340)
9. Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS et al. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 2002; 51: 3090-3094.
10. Sung SH, Ziyadeh FN, Wang A et al. Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol 2006; 17: 3093-3104. (Pubitemid 44707769)
11. Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129-1136. (Pubitemid 351398487)
12. Gurevich F, Perazella MA. Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med 2009; 122: 322-328.
13. Nakagawa T. Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease. Am J Physiol Renal Physiol 2007; 292: F1665-F1672. (Pubitemid 47105355)
14. Tufró A. VEGF spatially directs angiogenesis during metanephric development in vitro. Dev Biol 2000; 227: 558-566.
15. Guan F, Villegas G, Teichman J et al. Autocrine VEGF-A system in podocytes regulates podocin and its interaction with CD2AP. Am J Physiol 2006; 291: F422-F428. (Pubitemid 44148132)
16. Shigehara T, Zaragoza C, Kitiyakara C et al. Inducible podocyte-specific gene expression in transgenic mice. J Am Soc Nephrol 2003; 14: 1998-2003. (Pubitemid 36909907)
17. Akeson AL, Greenberg JM, Cameron JE et al. Temporal and spatial regulation of VEGF-A controls vascular patterning in the embryonic lung. Dev Biol 2003; 264: 443-455. (Pubitemid 37490980)
18. Fioretto P, Mauer M. Histopathology of diabetic nephropathy. Semin Nephrol 2007; 27: 195-207. (Pubitemid 46550314)
19. Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 2008; 75: 346-359. (Pubitemid 350298459)
20. Shalaby F, Rossant J, Yamaguchi TP et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995; 376: 62-66.
21. Breyer MD, Bö ttinger E, Brosius 3rd FC et al. AMDCC: mouse models of diabetic nephropathy. J Am Soc Nephrol 2005; 16: 27-45. (Pubitemid 43073154)
22. Liu E, Morimoto M, Kitajima S et al. Increased expression of vascular endothelial growth factor in kidney leads to progressive impairment of glomerular functions. J Am Soc Nephrol 2007; 18: 2094-2104. (Pubitemid 47041075)
23. Castro MM, Rizzi E, Figueiredo-Lopes L et al. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 2008; 198: 320-331. (Pubitemid 351707391)
24. Chen S, Kasama Y, Lee JS et al. Diabetes 2004; 53: 2939-2949.
25. Kaji T, Yamamoto C, Oh-i M et al. The vascular endothelial growth factor VEGF165 induces perlecan synthesis via VEGF receptor-2 in cultured human brain microvascular endothelial cells. Biochem Biophys Acta 2006; 1760: 1465-1474. (Pubitemid 44374222)
26. Hirose K, Osterby R, Nozawa M et al. Development of glomerular lesions in experimental long-term diabetes in the rat. Kidney Int 1982; 21: 689-695. (Pubitemid 12124298)
27. Nerlich A, Schleicher E. Immunohistochemical localization of extracellular matrix components in human diabetic glomerular lesions. Am J Pathol 1991; 139: 889-899.
28. Koop K, Eikmans M, Baelde HJ et al. Expression of podocyte-associated molecules in acquired human kidney diseases. J Am Soc Nephrol 2003; 14: 2063-2071. (Pubitemid 36909914)
29. Kalluri R. Proteinuria with and without renal glomerular podocyte effacement. J Am Soc Nephrol 2006; 17: 2383-2389. (Pubitemid 44300954)
30. Benigni A, Gagliardini E, Tomasoni S et al. Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy. Kidney Int 2004; 65: 2193-2000.
31. Verma R, Kovari I, Soofi A et al. Nephrin ectodomain engagement results in Src kinase activation, nephrin phosphorylation, Nck recruitment, and actin polymerization. J Clin Invest 2006; 116: 1346-1359.
32. Uchida K, Suzuki K, Iwamoto M et al. Decreased tyrosine phosphorylation of nephrin in rat and human nephrosis. Kidney Int 2008; 73: 926-932. (Pubitemid 351458318)
33. Jones N, Blasutig IM, Eremina V et al. Nck adaptor proteins link nephrin to the actin cytoskeleton of kidney podocytes. Nature 2006; 440: 818-823.
34. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2006; 6): 669-676. (Pubitemid 36749215)
35. Zeng H, Dvorak HF, Mukhopadhyay D. Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) receptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways. J Biol Chem 2001; 276: 26969-26979.
36. Olsson AK, Dimberg A, Kreuger J et al. VEGF receptor signaling-in control of vascular function. Nat Rev Mol Cell Biol 2006; 7: 359-371.
37. Kosaras B, Snyder E. Electron microscopy and lac-Z labeling. Methods Mol Biol 2002; 198: 157-175.
38. Ku CH, White KE, Dei Cas A et al. Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice. Diabetes 2008; 57: 2824-2833.
39. Fitch RM, Rutledge JC, Wang YX et al. Synergistic effect of angiotensin II and nitric oxide synthase inhibitor in increasing aortic stiffness in mice. Am J Physiol Heart Circ Physiol 2006; 290: H1190-H1198.
40. Giulietti A, Overbergh L, Valckx D et al. An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods 2001; 25: 386-401. (Pubitemid 34164011)
41. Tufro A, Teichman J, Villegas G. Crosstalk between VEGF-A/VEGFR2 and GDNF/RET signaling pathways. Biochem Biophys Res Commun 2007; 358: 410-416. (Pubitemid 46766597)